🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07178951
Recruiting Not applicable

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis

NCT07178951 · tracked via the Priya Life Science Canada tracker
Sponsor
FUSMobile Inc
Phase
Not applicable
Started
2026-09-09
Last updated
2026-09-17

Condition(s) studied

Osteoarthritis (OA) of the KneeKnee Pain ArthritisChronic Knee Pain

Investigational drug(s) / intervention(s)

Neurotomy of the medial sensory articular branches

Neurotomy of the medial sensory articular branches: Non-invasive thermal ablation of the medial sensory articular branches of the knee joint

Study summary

This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Moderate to severe, predominantly medial chronic knee pain 2. Age adult \>18 years old 3. WOMAC Score of 30 or higher 4. NRS\>6 with ambulation 5. Radiological confirmation of knee osteoarthritis (Kellgren-Lawrence Scale: 2-4) 6. Participants in whom the measured skin to bone depth is 2-6 cm using imaging ultrasound and ultrasound gel pad in the upper medial and lower medial joint capsule targets. Exclusion Criteria: 1. Individuals meeting any of the following criteria are not eligible for participation in this study: 2. Individuals after any surgery associated with altered integrity of bone structure 3. Individuals with severe pain in the second knee 4. Individuals unable to understand and complete the research questionnaires in the official language 5. Individuals presenting with any severe medical condition preventing the participant from safely and effectively being treated in the study or reporting study outcomes, per PI decision 6. Individuals with extensive scarring of the skin and tissue overlying the treatment area 7. Individuals enrolled in or planned to be enrolled in another clinical trial during the duration of this research project 8. Individuals with active inflammatory (e.g., rheumatoid) arthritis 9. Individuals with concomitant mental health disorders, excluding compensated mood disorders 10. Individuals with altered perception and processing of pain: Average NRS \> 9, PCS\>30, SSS-8 \> 11, CSI\>40 \[46\], \[47\], \[48\] 11. Individuals with a first-degree family member already enrolled in this study 12. Individuals who are scheduled for any interventional/surgical procedure within 3 months from the screening date, excluding trivial surgeries (e.g., cataract, skin tumors) 13. Inability to attend follow-up visits and physiotherapy due to travel distance or other restrictions 14. Symptomatic multifocal nociplastic chronic pain (e.g., fibromyalgia, generalized osteoarthritis) or any other chronic pain condition that could influence symptoms. 15. Participants who have undergone radiofrequency ablation of the genicular nerves in the planned treatment limb within the preceding 6 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Unika Medical Centre North York Ontario Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07178951 on ClinicalTrials.gov ↗ ← All trials in Canada